14 questions to assess safety skills in a child with autism

Lebrikizumab improves itch, sleep interference, and skin pain in atopic dermatitis patients previously treated with dupilumab, offering a new treatment option.

An overview of commercially available infant cardiorespiratory monitors and pulse oximeters in the home.

The newly-approved indication is for children aged 4 years and older who weigh 33 < 66 lbs, expanding on the August 9, 2024 approval in children at least 66 lbs.

According to data presented at AAAAI, berotralstat demonstrated a well tolerated safety profile and early and sustained reductions in monthly HAE attacks among patients aged 2 to under 12 years.